UBS lowered the firm’s price target on Gentex (GNTX) to $25 from $26 and keeps a Neutral rating on the shares. Gentex reported “good” Q4 results and the 2026 outlook was in line with estimates, the analyst tells investors in a research note.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GNTX: